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Summary  
The EBMT risk score is an established tool successfully used in the prognosis of survival 
post HSCT and is applicable for a range of haematological disorders. One of its main 
advantages is that score generation involves summation of clinical parameters that are 
available pre-transplant.  However, the EBMT risk score is recognised as not being optimal.   
Previous analyses, involving patients with various diagnoses, have shown that non-HLA gene 
polymorphisms influence outcome after allogeneic  HSCT.  This study is novel as it focuses 
only on patients having acute leukaemia (N=458) and attempts to demonstrate how non-HLA 
gene polymorphisms  can be added to the EBMT risk score in a Cox regression model to 
improve prognostic ability for overall survival.  The results of the study found that three 
genetic factors improved EBMT risk score.  The presence of MAL (rs8177374) allele T in the 
patient, absence of glucocorticoid receptor haplotype (consisting of rs6198, rs33389 and 
rs33388) ACT in the patient and absence of heat shock protein 70-hom (+2437) (rs2227956) 
allele C in the patient were associated with decreased survival time.  When compared to the 
EBMT risk score, the scores combining EBMT risk score with the genetic factors had an 
improved correlation with clinical outcome and better separation of risk groups.  A 
bootstrapping technique, involving repeated testing of a model using multiple validation sets, 
also revealed that the newly proposed model had improved predictive value when compared 
to the EBMT risk score alone. 
Results support the view that non-HLA polymorphisms could be useful for pre-transplant 
clinical assessment and provide evidence that polymorphisms in the recipient genotype may 
influence incoming donor cells, suppressing the initiation of the graft versus leukaemia effect 
and reducing survival.   
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Introduction 
Allogeneic haematopoietic stem cell transplantation (HSCT) is the principal curative therapy 
for disorders of the haematopoietic system but it is still associated with substantial morbidity 
and mortality (Copelan (2006), Gratwohl et al. (2007)) with a survival rate of 40-60% 
(Balavarca et al. (2015)).  Five main clinical factors influencing outcome after HSCT have 
been established by the European Group for Blood and Marrow Transplantation (EBMT).  
These EBMT-factors (patient age, stage of the disease, time interval from diagnosis to 
transplant, histocompatibility and donor and patient gender combination) have been 
successfully utilised in a clinical risk score (EBMT risk score) (Gratwohl (2012)) for all 
patients undergoing HSCT for a haematological disorder (Gratwohl et al. (2009)) 
(Supplementary Table 1).   
Recently several groups, including ourselves, have used both small cohorts (Dickinson (2008), 
Mullally &  Ritz (2007)) and genome-wide association studies (GWAS) (Chien et al. (2012)) 
to demonstrate that polymorphisms within non-HLA genes are predictive of HSCT outcome.  
The effect of gene polymorphisms may be influenced by year of transplant; transplant protocols 
have been modified over the last ten years due to increased use of reduced intensity 
conditioning, increased use of peripheral blood stem cells rather than bone marrow and 
increased age of the patient at time of transplant (Feinstein et al. (2001)) thus altering the 
biology of HSCT.  
In this study we investigated the role of non-HLA polymorphisms in a cohort of acute 
leukaemia patients with HLA matched sibling and matched unrelated donors.  The influence 
of change in transplant protocols over time was also assessed.  The results from the non-HLA 
genetic analysis were used to derive a novel (and validated) statistical model for overall 
survival which integrated non-HLA genetics into the EBMT risk score.  Gene polymorphisms 
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were also investigated for their association with non-relapse mortality, relapse and acute and 
chronic graft versus host disease.  
All patients and donors gave informed consent in accordance with EBMT guidelines and the 
Declaration of Helsinki.  The protocol was approved by the Local Research Ethics Committee 
at the co-ordinating centre (Newcastle upon Tyne).  
Materials and Methods  
Patients 
Data were available from a total of 458 adult acute leukaemia patients (330 acute myeloid 
leukaemia, 123 acute lymphoblastic leukaemia, 3 acute biphenotypic leukaemia and 2 acute 
undifferentiated leukaemia) and were collected prospectively from 8 European transplant 
centres. Transplants were conducted between 1983 and 2005.   All clinical data were collected 
from the EBMT database ProMIse.  In this cohort, 58% of patients had died and 30% of patients 
had relapsed. HLA typing was determined by standard technologies using serology or 
molecular typing.  Of the 458 patients, 29% received reduced intensity conditioning and 34% 
were T cell depleted. All patients received standard comparative supportive care across centres. 
The median follow up time was 77 months. Causes of death were stated as relapse (46%), acute 
respiratory distress syndrome (ARDS)/infection (21%), graft versus host disease (GvHD) 
(18%) and ‘other’ (15%).  Clinical relapse was defined as hematologic, cytogenetic or 
molecular relapse (Branford (2007)). Patient and donor characteristics are presented in Table 
1. 
Genotyping for cytokine polymorphisms 
Archived frozen peripheral blood mononuclear cells were used for the preparation of DNA. 
Genotyping was carried out by Kbioscience (http://www.kbioscience.co.uk) who used 
fluorescence-based competitive PCR technology (KASPar) and designed the assays for the 
SNPs based on the DNA sequence (50 bases) either side of the SNP. Genotypes were 
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available for 32 non-HLA candidate polymorphisms from 20 genes (Supplementary Table 2). 
These SNPs were chosen according to findings on smaller patient cohorts by our coordinating 
centre in Newcastle (ESR1 (Middleton et al. (2003)), IFNG (Pravica et al. (1999)), IL1RN 
(Hurme &  Santtila (1998)), IL4 (Walley &  Cookson (1996)), IL6 (Cavet et al. (2001),Yee et 
al. (2009)), IL10 (Morse et al. (1999)), IL13 (Graves et al. (2000)), TNF (Imboden et al. 
(2006)), TNFRSF1B (Stark et al. (2003)) and VDR (Middleton et al. (2002))) and according 
to findings by other HSCT groups (MAL (Rocha et al. (2007)), MDR1 (Kim et al. (2006))  
and NOD2 (Holler et al. (2004)).  Candidate SNPs were also selected according to previous 
disease association studies in autoimmune (CD14 (Klein et al. (2002)), GCR (Derijk et al. 
(2001), Stevens et al. (2004)), HSP70-hom (Bogunia-Kubik &  Lange (2005)) and IL12B 
(Cargill et al. (2007))) or inflammatory disease and GvHD (Novota et al. (2011)) (C3 (Park 
et al. (2009)), LOX1 (Wang et al. (2011)) and CD91 (Chalmers et al. (2010))). 
The majority of the cohort after the year 2000 had high-resolution tissue typing for HLA 
Class I A,B,C and Class II DP,DQ and DR. 
Statistical analysis 
The impact of selected non-HLA genetic factors on survival, non-relapse mortality (NRM) 
(Iacobelli (2013)), relapse and GvHD was assessed using Kaplan-Meier, Cox regression and 
competing risks (Marubini &  Valsecchi (1996)) techniques.   
For modelling overall survival, biallelic SNPs were considered under the additive, dominant 
and recessive modes of inheritance (Chien, et al. (2012)). For a specific SNP, the mode 
showing the strongest association with survival was entered into the final model.  All available 
genetic variables were used as candidates for Cox regression model building, these were 
entered into a stepwise variable selection modelling procedure alongside the EBMT risk score.  
A significance level of 0.05 was used for variable entry and 0.1 for removal. 
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Predictive accuracy of the models was quantified using the concordance index (C-index) 
(Harrell et al. (1982))  and prediction error (i.e. 0.632+ bootstrap estimator) (Gerds &  
Schumacher (2007)).  A larger value of the concordance index (C-index) means that lower 
risk score correlates with longer survival time (C-index=1 means perfect predictive 
discrimination; C-index=0.5 means no predictive discrimination).  The method of prediction 
error curve generation utilises a bootstrapping procedure whereby a model is generated using 
training data and validated using a test data set. The procedure is repeated 1000 times and, for 
each repetition, a training set of size N is extracted from the full data set (also of size N) 
using sampling with replacement; the remaining data (not used in the training sample) act as 
a test set.  For each iteration, differences are found between actual and predicted responses in 
the test set and essentially an average residual is found. When several models are compared, a 
lower prediction error curve signifies that the associated model has a better predictive 
performance 
R (v3.1.2), Minitab (v17), SAS (v9.4) and SPSS-23 were used for the computations.  
Results 
Clinical Characteristics 
As transplant protocols have changed with time, we assessed clinical differences in patients 
treated up to and after the year 2000.  The Chi-square test was employed for this task utilising 
exact P-values (Table 1).  
The majority of patients in this study underwent HSCT after the year 2000 (63%).  Transplants 
post year 2000 involved more patients and donors over 40 years of age, more  HLA-matched 
unrelated donors, more peripheral blood stem cell transplants, more T cell depleted transplants 
and more reduced intensity conditioning (RIC) protocols (Table 1).   
Analysis of Genetic Factors  
9 
 
Overall survival was initially studied. Kaplan-Meier survival curves and associated log rank 
tests were generated for each individual gene polymorphism.  Variables showing a significant 
difference between survival curves (P-value < 0.05) are displayed in Table 2 and include 
MAL (rs8177374), the glucocorticoid receptor (GCR) haplotype (consisting of rs6198, 
rs33389 and rs33388), IL1RN (rs419598) and IL4 (rs2243250) in the patient together with the 
IL10 haplotype (consisting of rs1800896, rs1800871 and rs1800872) and MDR1 (rs1045642) 
in the donor.   
Model Construction 
The multivariate Cox regression model was generated with N=204 (a reduction from N=458 
due to missing data).  A missing value assessment was carried out to check that there was no 
difference between the group of cases omitted and the group of cases included for statistical 
analysis.  The difference between survival functions for the two groups was non significant 
(P-value = 0.376) (results not shown).  Additional results showing the comparison of the 
clinical data are displayed in Supplementary Table 3.  
Single nucleotide polymorphisms (SNPs) in three genes were found to improve the goodness 
of fit of the model when viewed alongside the EBMT risk score.  Presence of MAL (rs8177374) 
allele T in the patient (HR:1.54, 95% CI:1.04-2.30), absence of the GCR haplotype (consisting 
of rs6198, rs33389 and rs33388) ACT in the patient (HR:0.67, 95% CI:0.46-0.98) and absence 
of heat shock protein 70-hom (HSP70-hom +2437) (rs2227956) allele C in the patient 
(HR:0.56, 95% CI:0.36-0.88) were associated with decreased survival time (Table 3). 
Univariate log rank tests for the individual predictors and the associated Kaplan-Meier plots 
are shown in Supplementary Figure 1.  Every predictor showed a log rank statistic with P-value 
<0.05 except patient HSP70-hom (+2437) (rs2227956) allele C (P-value = 0.245).  This 
variable was therefore more weakly associated with overall survival when viewed on its own 
but an important predictor when viewed alongside other variables.  Predictors having univariate 
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statistics with P-value < 0.25 are deemed to be satisfactory candidate variables in multivariate 
modelling (Hosmer &  Lemeshow (2000)). 
The resulting model enabled an integer score (clinical-genetic-score) to be assigned to each 
patient.  The clinical-genetic-score was calculated via a summation process of the model’s 
individual elements (Supplementary Section A).  To make the scoring instrument easier to use 
in a clinical setting, individual elements were obtained by dividing the regression coefficients 
by the coefficient of the EBMT risk score and rounding to the nearest whole number (Table 3, 
Supplementary Section A). A higher risk score indicated a worse prognosis.  
For the cases in the study set, the EBMT risk score ranged from 0 to 7 (low to high risk); 
clinical-genetic-scores ranged from 1 to 13 (no patient had the minimum possible score of 0 or 
maximum possible score of 14).  After observing resulting Kaplan-Meier curves for the 
individual clinical-genetic-scores and grouping categories which naturally fell together (results 
not shown), ‘low risk’ could be categorized as having scores 1-6, ‘intermediate risk’: scores 7-
8  and ‘high risk’: scores 9-13. A Kaplan-Meier plot displaying good separation of the three 
resulting survival curves is shown in Figure 1A.  Furthermore the hazard ratio (HR) in a Cox 
regression significantly increased when compared to the low risk group (intermediate risk HR: 
1.70, 95% CI: 1.10-2.63; high risk HR: 3.25, 95% CI: 2.06-5.12).  A Kaplan-Meier plot for the 
EBMT risk score is also provided for comparison (Figure 1B), it was clear that the risk 
categories of the clinical-genetic-score had better separated (and consistently ordered) survival 
curves when compared to those of the EBMT risk score for this data set. 
Next, prediction error curves (utilising a bootstrapping procedure and incorporating 
validation sets) were used to compare a model containing the single EBMT risk score, a 
model containing EBMT risk score and the three polymorphisms and a model containing no 
factors (i.e. the Kaplan-Meier curve).  A comparison of each model is given in Figure 2.  The 
lower prediction error curve for the model containing EBMT risk score and the three 
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polymorphisms signified that it had a better predictive value.  Furthermore, the C-index  
showed that the risk score groups generated from a model containing SNPs correlated better 
with actual survival time when compared with a model containing the EBMT risk score alone 
(0.62 versus 0.59, P-value=0.012), the hazard ratio was also higher (HR: 1.80, 95% CI:1.43-
2.26 versus HR: 1.21, 95% CI: 1.10-1.40). 
Association with Other Outcomes 
After further analysis of the SNPs for association with NRM and relapse, Gray’s test (Gray 
(1988))  indicated that presence of MAL (rs8177374) allele T in the patient (P-value = 0.031) 
and absence of the GCR haplotype (consisting of rs6198, rs33389 and rs33388) ACT in the 
patient (P-value = 0.026) were associated with an increased incidence of relapse 
(Supplementary Tables 4A-B).  The genetic variables were also studied for their association 
with acute GvHD I-IV, II-IV, III-IV and chronic GvHD.  It was found that the presence of the 
GCR haplotype (consisting of rs6198, rs33389 and rs33388) ACT in the patient was weakly 
associated with chronic GvHD (P-value = 0.075). 
Discussion 
One of the problems of SNP association studies in HSCT is the heterogeneity of the cohort in 
terms of diagnosis, type of conditioning, GvHD prophylaxis and donor type.  For this reason, 
this study focused on one disease group, acute leukaemia.  For this disease, a risk scoring 
instrument was established which included three polymorphisms together with the EBMT 
risk score. Presence of MAL (rs8177374) allele T in the patient, absence of the GCR 
haplotype (consisting of rs6198, rs33389 and rs33388) ACT in the patient and absence of 
HSP70-hom +2437 (rs2227956) allele C in the patient were associated with decreased 
survival. The subsequent score assigned to each patient was termed the clinical-genetic-score 
and could be easily derived by means of summation of risk score points assigned to each of 
the model’s elements.  Moreover, in practice, polymorphisms in the patient could be typed at 
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the same time as donor tissue is typed (pre-transplant) and this makes the clinical-genetic-
score no less accessible than the EBMT risk score.  Patients could be assigned to low, 
intermediate and high risk score categories based on their clinical-genetic-score and 
identification of patients in the high risk group would ensure that they had a reduced time to 
transplant from diagnosis, younger donors, fully matched HLA donors (Kollman et al. 
(2001)) (all associated with improved survival) and increased monitoring for 
GvHD/infection.   
As expected, there was a strong correlation between the EBMT risk score and clinical-
genetic-score (Spearman’s r = 0.676; P-value < 0.0005, N=204) but validation of the models 
via a bootstrapping procedure indicated that the clinical-genetic-score had improved 
predictive value when compared to the EBMT risk score alone and, additionally, prognostic 
risk categories derived from the clinical-genetic-score showed more distinct separation of 
survival curves.  This result also held when data were divided according to transplant date 
with the clinical-genetic-score categories having a higher C-index when compared to the 
EBMT risk score (0.62 versus 0.57, up to year 2000; 0.63 versus 0.61, post year 2000) and 
displaying consistent order as regards pattern of survival curves (Supplementary Figures 2A-
D ).  Additionally, the clinical-genetic-score appeared to highlight how transplants post 2000 
have resulted in improved probability of survival for the intermediate risk group 
(Supplementary Figure 2B). 
Holtick et al. (2008) found that patients homozygous for the T allele of MAL (rs8177374) had 
an increased risk of relapse whilst, in the donors, the presence of the T allele resulted in less 
cGvHD.  Interestingly, Rocha et al. (2007) found, that presence of the T allele of rs8177374 
in donors resulted in less transplant related mortality.  The T allele is regarded in the 
literature as the inflammatory allele and individuals heterozygous for this SNP have increased 
protection from infection. Patients transplanted from donors with the T allele have also been 
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shown to have a lower incidence of fungal infections, lower incidence of acute GvHD and 
improved overall survival (Rocha, et al. (2007)). The MAL protein was originally identified 
in intermediate and late stages of T-lymphocyte differentiation (Alonso &  Weissman (1987)) 
and is an internal component of glycolipid-enriched membrane domains in T-lymphocytes 
(Millán et al. (1997)). It may be important in T cell signalling and thus associated with 
reduced or improved survival depending on the role of the T cells e.g. associated GvL or 
GvHD effects. It is also important in the innate immune response and it is involved in Toll-
like receptor (TLR) 2 and 4 signalling (Yamamoto et al. (2002)). 
The GCR binds glucocorticoids in the cytoplasm and transports them to the nucleus where 
they influence the expression of many inflammatory genes such as interleukin (IL) IL1, IL2, 
IL3, IL6, IL8 and TNF causing their down regulation (Chikanza et al. (2003)). In addition, 
glucocorticoids can also induce the transcription of anti-inflammatory genes including IL4, 
IL10 and IL13 (Chikanza, et al. (2003)). The ACT haplotype is made up of two of the 
putative GC resistant, inflammatory alleles, the C allele of rs33389 and the T allele of 
rs33388. 
There is a well-documented association between the occurrence of cGvHD and reduced 
relapse risk in HSCT (Signori et al. (2012)) and this is borne out in our results with the ACT 
haplotype of the GCR in the patient showing a trend to association with cGvHD and the 
absence of this haplotype also being associated with decreased survival and with increased 
relapse. This putative inflammatory haplotype might be aiding the graft versus leukaemia 
(GvL) effect as well as cGvHD and therefore the absence of this haplotype would result in a 
more immunosuppressed phenotype in the patient leading to decreased survival. 
There was a trend towards an association between recipient HSP70-hom +2437 (rs2227956) 
genotype TT and incidence of acute GvHD (P-value = 0.127).  Past studies have shown a 
relationship between another HSP70-hom SNP, rs2075800, in recipients and GvHD with 
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genotype AA presenting more frequently with grade II to IV toxic lesions and acute GvHD 
(Bogunia-Kubik &  Lange (2005)). Another study has shown an association between HSP70-
hom +2437 (rs2227956) and treatment related mortality with the TT genotype in patients 
displaying a protective effect but the study was limited to a small cohort (N=147) (Kim et al. 
(2010)). HSP70-hom belongs to a highly conserved family of proteins, intracellular HSPs 
function as molecular chaperones facilitating the folding or transport of other proteins 
following physical or chemical stress (Matouschek (2003)). Extracellular HSPs are important 
in the cellular immune response acting as carrier molecules for antigen peptides (Srivastava 
et al. (1994)) and they may by themselves activate the innate immune response (Asea et al. 
(2000)). 
This AL data set forms part of a previously analysed larger cohort which included other 
disease types: CML, lymphoma, plasma cell neoplasia, myelodysplasia syndrome and 
chronic myelomonocytic leukaemia (Balavarca, et al. (2015)).  Here, a prognostic index for 
overall survival was also derived using the EBMT risk score and additional genetic 
polymorphisms (haplo-genotype ACC/ACC of IL10 in donors, MAL rs8177374 in patients, 
ESR1 rs9340799 in patients and IL6 rs1800795 in donors).  MAL rs8177374 in patients is 
common to both models with allele T being associated with reduced overall survival. 
Additionally, univariate similarities between the two cohorts were also present with a 
protective effect being observed for IL10 haplo-genotype ACC/ACC, IL4 rs2243250 (allele 
T) and GCR rs33388 (allele T) and a reduced survival effect for MAL rs8177374 (allele T) 
and IL10 rs1800896 (allele G). Although, the purpose of the current (acute leukaemia) study 
is not to directly contrast and compare the two statistical models, we did find clear 
similarities when they were viewed alongside the established EBMT risk score (better 
differentiation of risk groups, increased predictive value and clear identification of improved 
survival probability for patients transplanted after 2000).  Both studies hence illustrate the 
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importance of including genetic as well as clinical information in a pre-transplant risk scoring 
procedure and reflect the influence of polymorphisms which suppress the immune response 
giving rise to reduced survival (possibly due to reduced GvL effects) (Dickinson et al. 
(2010), Pearce et al. (2012), Balavarca, et al. (2015)).  
In conclusion, the established EBMT risk score, although easily accessible pre-transplant, is 
recognised as not being optimal.  Utilising clinical and genetic factors could be one way to 
improve pre-transplant clinical risk assessment.   In a recent review, the relationship of the 
EBMT risk score with outcome was indeed shown to depend on other factors such as CMV 
status and Karnofsky score (Gratwohl (2012)).  In future, further SNPs could be identified via 
meta-analysis and these could be viewed in conjunction with specific protein levels and/or 
mRNA and microRNA levels of putative biomarkers.  In addition, large cohort analysis could 
enable combined patient and donor SNPs to be used as supplementary predictors in HSCT. 
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Figure Legends 
Figure 1 Kaplan-Meier survival plots for risk groups. Figure A Derived from the clinical-
genetic-score. Grey dashed line = scores 9-13, grey solid line = scores 7-8, black solid line = 
scores 1-6.  Figure B Derived from the EBMT risk score. Grey dotted line = scores 6-7, grey 
dashed line = score 5, grey solid line = score 4, black dotted line = score 3, black dashed line 
= score 2, black solid line = score 0-1. Crosses represent censored observations.  N=204.  It is 
illustrated that the risk categories of the clinical-genetic-score had better separated (and 
consistently ordered) survival curves when compared to those of the EBMT risk score. 
Figure 2 Plot of prediction error curve for model including EBMT risk score and 3 
polymorphisms compared to (i) EBMT risk score and (ii) a model containing no factors 
(Kaplan-Meier curve). N=204. Solid black line: Kaplan-Meier curve; solid grey line: EBMT 
risk score; dashed grey line: model including EBMT risk score and 3 polymorphisms. The 
lower prediction error curve for the model containing EBMT risk score and the three 
polymorphisms showed that it had a better predictive value.   
 


Table 1 Clinical characteristics of patients and donors prior to HSCT (N=458) 
    Year of Transplant P-value
c 
Factors Categories No.         (%)  ≤ 2000 >2000  
    No.     (%) No.     (%)  
No of patient/donor         171 287   
Age of patient at 
transplantation (years)a,b 
<20 years 26 (5.7)  17 (9.9) 9 (3.1) <0.001 
20-40 years 226 (49.3)  107 (62.6) 119 (41.5)  
>40 years 206 (45.0)  47 (27.5) 159 (55.4)  
          
Age of donor (years)b <20 years 26 (5.7)  21 (12.6) 5 (1.8) <0.001 
 20-40 years 261 (57.0)  97 (58.1) 164 (59.0)  
 >40 years 158 (34.5)  49 (29.3) 109 (39.2)  
 NA 13 (2.8)  4  9   
          
Patient/donor gender 
combinationa 
Male/female 93 (79.5)  33 (19.3) 60 (21.0) 0.719 
Other 364 (20.3)  138 (80.7) 226 (79.0)  
 NA 1 (0.2)  0  1   
          
Type of donora,b Sibling 241 (47.4)  113 (66.1) 128 (44.6) <0.001 
 HLA-matched unrelated(MUD) 217 (52.6)  58 (33.9) 159 (55.4)  
          
Haematological disease 
Acute Biphenotypic leukaemia 3 (0.7)  2 (1.2) 1 (0.3) 0.547 
Acute Lymphoblastic leukaemia 123 (26.9)  47 (27.5) 76 (26.5)  
Acute Myeloid leukaemia 330 (72.1)  122 (71.3) 208 (72.5)  
 Acute Undifferentiated leukaemia 2 (0.4)  0 (0.0) 2 (0.7)  
          
Source of stem cellsb Bone Marrow 207 (45.2)  138 (83.1) 69 (25.5) <0.001 
 Peripheral blood 229 (50.0)  28 (16.9) 201 (74.2)  
 Both sources 1 (0.2)  0 (0.0) 1 (0.4)  
 NA 21 (4.6)  5  16   
          
Patient/donor CMV 
status 
Negative/Negative 136 (29.7)  56 (34.4) 80 (28.5) 0.202 
Other 308 (67.2)  107 (65.6) 201 (71.5)  
 NA 14 (3.1)  8  6   
          
Stage of disease at 
transplantationa 
Early 185 (40.4)  77 (48.1) 108 (43.9) 0.715 
Intermediate 92 (20.1)  35 (21.9) 57 (23.2)  
 Late 129 (28.2)  48 (30.0) 81 (32.9)  
 NA 52 (11.4)  11  41   
          
Time from diagnosis to 
transplanta 
≤12 months 330 (72.1)  124 (73.8) 206 (76.3) 0.570 
>12 months 108 (23.6)  44 (26.2) 64 (23.7)  
 NA 20 (4.4)  3  17   
          
T cell depletionb T cell depletion  154 (33.6)  28 (16.4) 126 (43.9) <0.001 
 No T cell depletion 304 (66.4)  143 (83.6) 161 (56.1)  
          
Conditioning regimenb 
 
Standard myeloablative 327 (71.4)  154 (90.1) 173 (60.3) <0.001 
Reduced Intensity (RIC) 131 (28.6)  17 (9.9) 114 (39.7)  
          
Transplantation centerb Vienna/Prague d 136 (30.0)  44 (25.7) 92 (32.1) <0.001 
 Regensburg/Munich d 121 (26.4)  32 (18.7) 89 (31.0)  
 Newcastle 123 (26.9)  83 (48.5) 40 (13.9)  
 Rostock 31 (6.8)  9 (5.3) 22 (7.7)  
 Paris 28 (6.1)  0 (0.0) 28 (9.8)  
 Barcelona 19 (4.1)  3 (1.8) 16 (5.6)  
  
Abbreviations:  HSCT = haematopoietic stem cell transplantation; NA = not available; No. = number. 
aClinical EBMT factor.  Categories displayed are those which are necessary for the derivation of the EBMT risk score.  
bSignificant difference between time periods (P-value ≤ 0.05).  
cP-values for Chi square (exact) test.  
 dThe centers of Vienna and Prague worked in close collaboration with each other - hence, both centres used similar treatment procedures. 
Likewise, there were collaborations between the centres of Regensburg and Munich.  
 
Table 2 Gene polymorphisms associated with overall survival with log rank test having P-value 
<0.05  
 
Genes  Polymorphisma Genotypes 
associated with 
decreased 
survival 
P-value MAF(%)b 
P-MAL  rs8177374(T)  TT or TC 0.003 15 
D-IL10  
haplotype GCC haplo-
genotypes 
including 
GCCc 
0.008 49 
P-GCR  
haplotype ACT  haplo-
genotypes 
excluding 
ACTd 
0.013 46 
D-MDR1  rs1045642(C)  CC 0.026 44 
P-IL1RN  rs419598(C)  CC or TC 0.030 25 
D-IL10  
haplo-genotype 
(ACC/ACC) 
haplo-
genotypes 
excluding 
(ACC/ACC) 
0.038 26 
P-IL4  rs2243250(T)  CC 0.043 16 
 
Abbreviations: Patients (P-) = gene from patient; D- = gene from donor; MAF= Minor Allele Frequency. 
aPolymorphisms ordered from lowest to highest P-value for log rank test. SNP rs numbers are followed by the minor allele. 
bMinor allele or haplotype frequency of the respective polymorphism tested for association with overall survival. 
cSNPS in the promoter region of the IL10 gene give the haplotypes GCC, ACC and ATA.  The SNP order for the haplotype designation is 
rs1800896, then rs1800871, then rs1800872.  The result for haplotype GCC is therefore equivalent to that for the  
presence of the G allele in rs1800896. 
dSNPs in the GCR gene give distinct haplotypes GCA,ACA,ATA and ACT.  The SNP order for the haplotype designation is rs6198, then 
rs33389, then rs33388.  The result for haplotype ACT is therefore equivalent to that for the presence of the T allele in rs33388. 
 
Table 3 Cox regression model with EBMT risk score and multiple polymorphisms for overall 
survival (N=204) 
 
Factorsa Coefficientb P-
value 
Hazard 
Ratioc 
Confidence 
Interval 
(95%) 
Risk Score Elementd 
EBMT risk score 0.20 0.001 1.22 1.08-1.37 0-7
e 
P-MAL 
rs8177374(T) 
dom.  
0.43 0.033 1.54f 1.04-2.30 TC or TT=2; CC=0 
P-GCR 
hapolotype 
(rs6198, rs33389, 
rs33388) ACT 
-0.39 0.049 0.67f 0.46-0.98 (ACT/GCA), 
(ACT/ACA),(ACT/ACT) 
or (ACT/ATA)=0; 
others=2 
P-HSP70-
hom(+2437) 
rs2227956(C) 
dom. 
-0.57 0.012 0.56f 0.36-0.88 CC or TC=0; TT=3 
 
Abbreviations: Patients (P-) = gene from patient.  
a For the SNPs listed, the rs number is followed by the minor allele and the respective genetic model: additive (add.), dominant (dom.), or 
recessive (rec.). 
b Regression coefficients from the Cox model, equivalent to the log of the hazard ratio. 
cAs EBMT risk score is evaluated using “histocompatibility” as one of its component elements and the percentage of related transplants 
receiving T cell depletion is lower than the percentage of unrelated transplants receiving T cell depletion, it may be argued that T cell 
depletion is exerting a confounding effect.  However, after adjusting for T cell depletion in the model, Hazard Ratios for the model factors 
are virtually unchanged (1.18, 1.62, 0.68, 0.57 respectively). 
d Elements are summed to obtain risk score for each patient (Supplementary Section A).  Minimum possible score = 0, maximum possible 
score=14.  
e Range of score values for EBMT risk score (Gratwohl et al., 2009). 
f Note the effect size, either protective or at risk, is larger than that of EBMT risk score. 
 
  
Supplementary Figure 1 Association with overall survival of individual gene polymorphisms 
included in prognostic model (Kaplan-Meier plots). Figure A Patient MAL rs8177374: grey 
line represents TT or TC, black line represents CC; log rank test p=0.003 , Figure B Patient 
GCR hapolotype (rs6198, rs33388, rs33389) ACT: grey line represents haplo-genotypes 
including ACT, black line represents haplo-genotypes excluding ACT; log rank test p=0.013, 
Figure C Patient HSP70-hom(+2437) rs2227956(C): grey line represents CC or TC, black 
line represents TT;  log rank test p=0.245. 
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Supplementary Figure 2  
Kaplan-Meier survival plots for risk groups derived from the clinical-genetic-score: Figure 
2A  ≤ year 2000 (N=78), Figure 2B > year 2000 (N=126). Grey dashed line = scores 9-13, 
grey solid line = scores 7-8, black solid line = scores 1-6.  Kaplan-Meier survival plots for 
risk groups derived from the EBMT risk score: Figure 2C ≤ year 2000 (N=78), Figure 2D > 
year 2000 (N=126). Grey dotted line = scores 6-7, grey dashed line = score 5, grey solid line 
= score 4, black dotted line = score 3, black dashed line = score 2, black solid line = score 0-
1. Crosses represent censored observations.   
It is illustrated that the risk categories of the clinical-genetic-score had consistently ordered 
survival curves when compared to those of the EBMT risk score. 
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Supplementary Table 1 Categorisations of the individual clinical elements that are utilised in 
the derivation of the EBMT risk score. 
 
Risk Factor  Score 
Pointsb 
Age of Patient (in years)   
 <20 0 
 20-40 1 
 >40 2 
   
Disease Stage   
 Early 0 
 Intermediate 1 
 Late 2 
   
Time interval for diagnosis to 
transplant (in months)a 
  
 ≤12 0 
 >12 1 
   
Donor Type   
 HLA-identical sibling donor 0 
 Unrelated donor, other 1 
   
Patient/donor gender combinationc   
 Male patient/female donor 1 
 All other 0 
 
adoes not apply for patient transplanted in first complete remission (score 0) 
bExample of derivation: Patient < 20 years , intermediate disease stage, HSCT  >12 months after diagnosis, unrelated donor, male patient 
female donor :  EBMT risk score = 0 + 1 + 1 + 1 + 1 = 4 
  
  
 
Supplementary Table 2 Description of non-HLA SNPs and other polymorphismsa 
(N=458). 
 
Gene name Chr. 
  SNP 
rs number 
Allele 
pair 
MA 
MAF %    Sample Sizeb  
  patient donor   patient donor   
Cluster determinant 14 (CD14) 5  rs2569190 G/A A 49 46  295 308  
Cluster determinant 91 (LPR1, CD91) 12  rs1799986 C/T T 15 15  297 315  
Complement component 3 (C3) 19  rs2230199 C/G G 20 20  309 322  
Estrogen receptor 1  (ESR1) 6  rs2234693 C/T C 45 45  382 378  
   rs9340799 G/A G 40 37  378 372  
Glucocorticoid receptor (NR3C1, GCR) 5  rs33389 C/T T 16 16  298 329  
   rs33388 T/A T 45 46  303 322  
   rs6198 G/A G 15 17  303 321  
Heat shock (HSPA1L, HSP70-hom)  6  rs2075800 G/A A 35 35  248 234  
protein 70 Hom   rs2227956 T/C C 16 17  292 286  
IL1 receptor antagonist (IL1RN) 2  rs419598 T/C C 25 22  386 388  
Interleukin 4 (IL4) 5  rs2243250 T/C T 16 16  361 358  
Interleukin 6 (IL6) 7  rs1800797 G/A A 38 41  327 354  
   rs1800796 C/G C 6 6  348 370  
   rs1800795 G/C C 39 41  390 389  
Interleukin 10 (IL10) 1  rs1800896 G/A G 48 49  346 356  
   rs1800872 A/C A 25 25  362 367  
Interleukin 12B (IL12B)  5  rs3212227 A/C C 23 19  264 285  
Interleukin 13 (IL13) 5  rs1800925 C/T T 19 17  314 340  
   rs20541 A/G A 19 22  340 350  
   rs1881457 C/A C 18 18  339 359  
Oxidized Low-Density (OLR1, LOX1)
  12  rs11053646 G/C G 7 8  300 324  
Lipoprotein Receptor 1            
MyD88-adapter-like (TIRAP, MAL) 11  rs8177374 T/C T 15 15  295 318  
Multi drug resistance (ABCB1, MDR1)  7  rs1045642 C/T C 48 44  280 292  
Nucleotide-binding (NOD2) 
oligomerization domain 
containing 2  
16  rs2066844 C/T T 5 6  322 328  
  rs2066845 C/G C 2 1  322 328  
  rs2066847 -/ C C 2 3  322 328  
Tumour necrosis factor (TNF) 6  rs1800629 G/A A 15 16  346 343  
Tumour necrosis factor  (TNFRSF1B) 
receptor 2 1  rs1061622 T/G G 25 24  355 373  
Vitamin D receptor (VDR) 12  rs731236 T/C C 39 39  370 387  
    rs7975232 C/A C
  49 47  377 396  
 
Abbreviations: Chr. = Chromosome number. MA = Minor allele. MAF = Minor allele frequency.   
aOther non-HLA polymorphisms were from genes: IFNG, MDR1(three allelic), GCR(haplotype) and IL10(haplotype). 
bAvailable sample size for patient’s or donor’s SNP. 
 
 
  
  
Supplementary Table 3 Comparing clinical variables for the subgroup used for modelling 
with the subgroup not used for modelling.  It was observed that there was no statistical 
difference between the group of cases omitted and the group of cases included for statistical 
analysis. 
 
 Used for Modelling  
 
Not Used for Modelling  P-value 
 Mean (SD) Mean (SD)  
Age of patient at 
transplantation (years) 
38.7 (11.44) 39.1 (12.71)  0.7091 
Age of donor at 
transplantation (years) 
36.0 (10.53) 38.1 (12.02) 0.0511 
Time from diagnosis 
to transplant (months) 
14.1 (24.98) 10.3 (12.03)  0.0511 
 % %  
Female donor to male 
patient 
19.6 20.9 0.8152 
CMV positivity in 
either patient or donor 
68.3 70.2 0.6802 
Source of stem cells 
(Bone Marrow) 
52.7 43.4 0.0552 
HLA-matched 
unrelated (MUD) 
transplant 
54.4 45.3 0.062 
Reduced Intensity 
Conditioning (RIC) 
29.4 28.0 0.7562 
T-cell depletion 33.8 33.5 1.0002 
Late stage disease at 
transplantation 
29.0 35.0 0.2412 
 
Abbreviation: SD = standard deviation 
1 Two sample t-test (2 sided test) 
2 Fisher’s Exact Test (2 sided test) 
 
 
  
Supplementary Table 4A Cumulative incidence of NRM at 2 years and 5 years post transplant for each level of a 
SNP.  Table 4B  Cumulative incidence of relapse at 2 years and 5 years post transplant for each level of a SNP.  
Associated P-values for Gray’s test are shown to establish if there is a significant difference between cumulative 
incidence curves. The presence of MAL (rs8177374) allele T in the patient and absence of the GCR haplotype 
ACT in the patient were associated with an increased incidence of relapse. 
A  
Genesa Genotype/Haplotype 2 years 
CIb 
5 years 
CIb 
P-valuec 
     
P-MAL 
rs8177374(T)  
 
CC 0.26 0.27 0.263 
 TT, TC 0.28 0.36  
     
P-GCR hapolotype 
(rs6198, rs33388, 
rs33389) ACT 
others 0.28 0.28 0.942 
 (ACT/GCA), 
(ACT/ACA),(ACT/ACT) 
or (ACT/ATA) 
0.26 0.31  
     
P-HSP70-
hom(+2437) 
rs2227956(C) 
TT 0.28 0.29 0.862 
 CC,TC 0.27 0.33  
     
 
B 
 
Genesa Genotype/Haplotype 2 years 
CIb 
5 years 
CIb 
P-valuec 
     
P-MAL 
rs8177374(T)  
 
CC 0.26 0.29 0.031 
 TT, TC 0.39 0.39  
     
P-GCR hapolotype 
(rs6198, rs33388, 
rs33389) ACT 
others 0.40 0.40 0.026 
 (ACT/GCA), 
(ACT/ACA),(ACT/ACT) 
or (ACT/ATA) 
0.25 0.27  
     
P-HSP70-
hom(+2437) 
rs2227956(C) 
TT 0.31 0.31 0.160 
 CC,TC 0.20 0.23  
     
  
 
Abbreviations: Patients (P-) = gene from patient; D- = gene from donor.  
a For the SNPs listed, the rs number is followed by the minor allele. 
bCI = cumulative incidence. 
cGray’s test. 
 
  
Supplementary Section  
A 
 
Risk score elements to be used in the derivation of the clinical-genetic-score (final column, 
Table 2) are derived from the coefficients of the Cox regression model.  The model took the 
form:  
0.196 x EBMT risk score + 0.434 x MAL rs8177374 - 0.394 x GCR haplotype ACT – 0.573 x HSP70-hom (+2437) 
Dividing each coefficient by 0.196 and rounding to the nearest whole number gives: 
EBMT risk score + 2 x MAL rs8177374 – 2 x GCR haplotype ACT – 3 x HSP70-hom (+2437) 
EBMT risk score can take values 0-7; MAL rs8177374 is coded CC = 0, TC or TT = 1; GCR 
haplotype ACT is coded ‘GCR ACT’ = 1, ‘others’ = 0; HSP70-hom (+2437) is coded TT = 0, 
CC or TC = 1. 
Risk score elements are thus: 
EBMT risk score:  
values 0,1,2,3,4,5,6 or 7 
MAL rs8177374 (patient):  
CC: 0 x 2 = 0 
 TC or TT: 1 x 2 = 2 
GCR haplotype ACT (patient): 
‘GCR ACT’: 1 x -2 = -2 ; scaling linearly:  -2 + 2 = 0 
‘others’: 0 x -2 = 0; scaling linearly:  0 + 2 = 2 
HSP70-hom (+2437) (patient): 
TT: 0 x -3 = 0; scaling linearly: 0 + 3 = 3 
CC or TC: 1 x -3 = -3; scaling linearly: -3 + 3 = 0 
The clinical-genetic-score is derived after summing the aforementioned risk score elements of 
the EBMT risk score and genetic factors (final column, Table 2). For example, a patient with 
  
EBMT risk score=3, presence of TC or TT  for MAL in the patient (contribution 2), presence 
of ACT/ATA for “GCR ACT” in the patient (contribution 0) and presence of TT for HSP70-
hom (+2437) in the patient (contribution 3) would have clinical-genetic-score= 3+2+0+3= 8. 
 
 
 
